| [1] |
Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure[J]. J Clin Oncol, 2007, 25(29):4575-4580.
|
| [2] |
Viganò L, Russolillo N, Ferrero A, et al. Evolution of long-term outcome of liver resection for colorectal metastases: analysis of actual 5-year survival rates over two decades[J]. Ann Surg Oncol, 2012, 19(6):2035-2044.
|
| [3] |
Adams RB, Aloia TA, Loyer E, et al. Selection for hepatic resection of colorectal liver metastases: expert consensus statement[J]. HPB, 2013, 15(2):91-103.
|
| [4] |
Chun YS, Vauthey JN. Local therapy for colorectal liver metastases: establishing today's level of evidence and defining tomorrow's roadmap[J]. J Natl Cancer Inst, 2017, DOI： 10.1093/jnci/djx018[Epub ahead of print]. |
| [5] |
Zorzi D, Mullen JT, Abdalla EK, et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases[J]. J Gastrointest Surg, 2006, 10(1):86-94.
|
| [6] |
Hamady ZZ, Lodge JP, Welsh FK, et al. One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach[J]. Ann Surg, 2014, 259(3):543-548.
|
| [7] |
Mise Y, Aloia TA, Brudvik KW, et al. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival[J]. Ann Surg, 2016, 263(1):146-152.
|
| [8] |
Moris D, Ronnekleiv-Kelly S, Rahnemai-Azar AA, et al. Parenchymal-sparing versus anatomic liver resection for colorectal liver metastases: a systematic review[J]. J Gastrointest Surg, 2017, 21(6):1076-1085.
|
| [9] |
Andreou A, Aloia TA, Brouquet A, et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy[J]. Ann Surg, 2013, 257(6):1079-1088.
|
| [10] |
Wakai T, Shirai Y, Sakata J, et al. Appraisal of 1 cm hepatectomy margins for intrahepatic micrometastases in patients with colorectal carcinoma liver metastasis[J]. Ann Surg Oncol, 2008, 15(9):2472-2481.
|
| [11] |
Sadot E, Groot Koerkamp B, Leal JN, et al. Resection margin andsurvival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?[J]. Ann Surg, 2015, 262(3):476-485.
|
| [12] |
Ayez N, Lalmahomed ZS, Eggermont AM, et al. Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2012, 19(5):1618-1627.
|
| [13] |
Adam R, Laurent A, Azoulay D, et al. Two-stage hepatectomy:a planned strategy to treat irresectable liver tumors[J]. Ann Surg, 2000, 232(6):777-785.
|
| [14] |
Wicherts DA, Miller R, de Haas RJ, et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases[J]. Ann Surg, 2008, 248(6):994-1005.
|
| [15] |
Narita M, Oussoultzoglou E, Jaeck D, et al. Two-stage hepatectomy for multiple bilobar colorectal liver metastases[J]. Br J Surg, 2011, 98(10):1463-1475.
|
| [16] |
Torzilli G, Adam R, Viganò L, et al. Surgery of colorectal liver metastases: pushing the limits[J]. Liver Cancer, 2017, 6(1):80-89.
|
| [17] |
Chua TC, Liauw W, Chu F, et al. Summary outcomes of two-stage resection for advanced colorectal liver metastases[J]. J Surg Oncol, 2013, 107(2):211-216.
|
| [18] |
de Santibañes E, Ardiles V, Alvarez FA. Associating liver partition and portal vein ligation for staged hepatectomy: a better approach to treat patients with extensive liver disease[J]. JAMA Surg, 2015, 150(10):929-930.
|
| [19] |
Alvarez FA, Ardiles V, de Santibañes M, et al. Associating liver partition and portal vein ligation for staged hepatectomy offers high oncological feasibility with adequate patient safety: a prospective study at a single center[J]. Ann Surg, 2015, 261(4):723-732.
|
| [20] |
Schadde E, Ardiles V, Robles-Campos R, et al. Early survival and safety of ALPPS: first report of the International ALPPS Registry[J]. Ann Surg, 2014, 260(5):829-836.
|
| [21] |
Schadde E, Ardiles V, Slankamenac K, et al. ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis[J]. World J Surg, 2014, 38(6):1510-1519.
|
| [22] |
Lam VW, Laurence JM, Johnston E, et al. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases[J]. HPB, 2013, 15(7):483-491.
|
| [23] |
Torzilli G, Procopio F, Botea F, et al. One-stage ultrasonographically guided hepatectomy for multiple bilobar colorectal metastases:a feasible and effective alternative to the 2-stage approach[J]. Surgery, 2009, 146(1):60-71.
|
| [24] |
Torzilli G, Cimino MM. Extending the limits of resection for colorectal liver metastases ENHANCED ONE STAGE SURGERY[J]. J Gastrointest Surg, 2017, 21(1):187-189.
|
| [25] |
Viganò L, Torzilli G, Cimino M, et al. Drop-out between the two liver resections of two-stage hepatectomy. patient selection or loss of chance?[J]. Eur J Surg Oncol, 2016, 42(9):1385-1393.
|
| [26] |
Torzilli G, Viganò L, Cimino M, et al. Is enhanced one-stage hepatectomy a safe and feasible alternative to the two-stage hepatectomy in the setting of multiple bilobar colorectal liver metastases? a comparative analysis between two pioneering centers[J]. Dig Surg, 2018, 35(4):323-332.
|
| [27] |
Van Cutsem E, Nordlinger B, Cervantes A, et al. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment[J]. Ann Oncol, 2010, 21 Suppl 5:v93-97.
|
| [28] |
Wang L, Sun Y, Zhao B, et al. Chemotherapy plus targeted drugs in conversion therapy for potentially resectable colorectal liver metastases: a meta-analysis[J]. Oncotarget, 2016, 7(34):55732-55740.
|
| [29] |
Sugihara K, Uetake H. Therapeutic strategies for hepatic metastasis of colorectal cancer: overview[J]. J Hepatobiliary Pancreat Sci, 2012, 19(5):523-527.
|
| [30] |
Scheffer HJ, Melenhorst MC, Echenique AM, et al. Irreversible electroporation for colorectal liver metastases[J]. Tech Vasc Interv Radiol, 2015, 18(3):159-169.
|
| [31] |
van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phaseⅢ trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus vevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2016, 34(15): 1723-1731.
|
| [32] |
Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phaseⅡ trial[J]. J Natl Cancer Inst, 2017, DOI: 10.1093/jnci/djx015[Epub ahead of print]. |
| [33] |
Hagness M, Foss A, Line PD, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer[J]. Ann Surg, 2013, 257(5):800-806.
|
| [34] |
Line PD, Hagness M, Berstad AE, et al. A novel concept for partial liver transplantation in nonresectable colorectal liver metastases[J]. Ann Surg, 2015, 262(1): e5-9.
|